65,437 trials
Carcinoma, Renal Cell
Primary: Time to Tumor Progression (TTP) Assessed Using Memorial Sloan-Kettering Cancer Center (MSKCC) Prognostic Factors Model — 3.1; 4.4; 8.0; 7.1 Months — p=0.860
Obesity · Venous Thrombosis · Anticoagulants
Primary: Peak Low Molecular Weight Heparin Anti-Xa Activity Level. — 0.25 IU/mL
Hepatitis · Hepatitis B, Chronic · Cirrhosis
Primary: Number of Participants With Clinical Response — 65; 62; 85; 82 Participants
Urethral Sphincter Activity
Primary: Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG — -18; 10; 11; -15 microvolts — p=>0.05
Healthy
Primary: Number of Participants With Fever Post Dose 1 (Days 1-8), Defined as an Oral Temperature ≥ 101°F (38.3°C). — 0; 0 Participants
Attention · Memory · Mood
Primary: Simple Reaction Time (Attention) — 287.7 ms
ADHD
Primary: ADHD Symptoms — 71.2; 78.4; 47.4; 55.5 Percent of item endorsement — p=<0.025
HIV Infections
Primary: Number of Participants With Viral Suppression: HIV-1 RNA < 50 Copies/mL During the Induction Phase — 20; 8 Participants
Obesity
Primary: Peak Growth Hormone (GH) on the GH Stimulation Test — 40.1; 25.2 ng/ml — p=<0.05
Asthma
Primary: Methacholine Responsiveness as Assessed by PC20, — 3.27; 8.71 mg/mL — p=0.048
Cancer · Heart Disease
Primary: Dietary Quality — 38.78; 41.18; 39.76 score — p=0.14
Type 2 Diabetes Mellitus
Primary: Number of Participants With Adverse Events. — 14; 11; 143; 146 participants
Partial Epilepsies
Primary: Number of Subjects Reporting at Least 1 Treat-Emergent Adverse Event (TEAE) During the Treatment Period (up to 8 Years) — 343 subjects
Rheumatoid Arthritis · Crohn's Disease
Primary: Intestinal Absorption of Calcium
Influenza
Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25